QUILT-3.076 trial (M-CENK): what clinicians have said so far
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
- NCT04898543 ↗
- Active, not recruiting
- ImmunityBio, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on QUILT-3.076 (M-CENK plus nogapendekin alfa inbakicept (N-803) in locally advanced or metastatic solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on QUILT-3.076 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Phase 1 Open-Label Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Metastatic Solid Tumor
- Interventions
- M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B); N-803 (Cohort 2 part B); Apheresis collection of MNCs (part A)
- Arms
- Cohort 1: Subjects newly diagnosed no prior therapy or prior first line treatment · Experimental
- Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors · Experimental
- Enrollment
- 50 (estimated)
- Primary outcomes
- Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis.
- Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of participants with clinically significant laboratory tests.
- Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by number of participants with abnormal vital signs.
- Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of TEAEs and SAEs after the first dose of M-CENK and the first dose of N-803 (M-CENK Dose Number 1)
- Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with clinically significant laboratory tests
- Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with abnormal vital signs
- Sponsor
- ImmunityBio, Inc.
- Start
- Jun 21, 2021
- Primary completion
- Feb 2, 2026
- Results posted
- No
- Registry record
- NCT04898543 · updated Nov 2, 2026